Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2005
03/03/2005WO2005019238A1 Novel azalide and azalactam derivatives and process for the production of the same
03/03/2005WO2005019237A1 Novel sulfenamides
03/03/2005WO2005019236A1 Novel sulfenamide oxides
03/03/2005WO2005019225A1 Process for producing compound having nk1 receptor antagonism and production intermediate thereof
03/03/2005WO2005019224A2 Novel antiinfective compounds
03/03/2005WO2005019221A1 4-cycloalkylaminopyrazolo pyrimidine nmda/nr2b antagonists
03/03/2005WO2005019220A2 Substituted imidazo[1,2-a]pyrazines as modulators of kinase activity
03/03/2005WO2005019219A1 Pyrrolopyrimidinone derivative
03/03/2005WO2005019218A1 Pyrrolopyrimidinethione derivative
03/03/2005WO2005019214A1 Novel antimicrobial aryloxazolidinone compounds
03/03/2005WO2005019211A2 Biaryl heterocyclic compounds and methods of making and using the same
03/03/2005WO2005019191A2 1, 1-dioxido-4h-1,2,4-benzothiadiazine derivate und verwandte verbindungen als inhibitoren der hcv polymerase zur behandlung von hepatitis c
03/03/2005WO2005019181A1 Migrastatin analog cell migration inhibitors
03/03/2005WO2005019177A1 Aminopiperidine amide derivatives as vla-1 integrin antagonists and uses thereof
03/03/2005WO2005019174A1 Acetylene derivatives as inhibitors of histone deacetylase
03/03/2005WO2005019167A2 Melanin concentrating hormone receptor antagonist
03/03/2005WO2005019166A2 Method of targeting a therapeutic agent
03/03/2005WO2005019163A2 Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
03/03/2005WO2005019157A1 Choline esters useful for the treatment of cognitive dysfunctions and enhancement of memory, learning and cognition
03/03/2005WO2005019151A1 Ppar modulators
03/03/2005WO2005018743A1 Use of an echinocandin antifungal agent in combination with a glycopeptide antibacterial agent
03/03/2005WO2005018678A1 Additives for tablet
03/03/2005WO2005018677A2 Use of combination of an epidermal growth factor receptor kinase inhibitor and cytotoxic agents for treatment and inhibition of cancer
03/03/2005WO2005018676A1 The combination of a serotonin reuptake inhibitor and a glycine transporter type 1 inhibitor for the treatment of depression
03/03/2005WO2005018675A1 Therapeutic agent for autoimmune disease
03/03/2005WO2005018674A1 Remedy for diseases associated with immunoglobulin gene translocation
03/03/2005WO2005018673A1 Pharmaceutical composition for preventing or remedying cardiac hypertrophy and cardiocascular disease caused thereby
03/03/2005WO2005018672A1 Drug containing chymase inhibitor as the active ingredient
03/03/2005WO2005018671A1 Cancer metastasis inhibitor
03/03/2005WO2005018670A1 Pharmaceutical composition comprising an alpha2delta ligand and an opioid receptor antagonist for the prevention and treatment of addiction in a mammal
03/03/2005WO2005018668A1 Method of inducing immune tolerance
03/03/2005WO2005018658A1 2-methylene-19-nor-vitamin d2 compounds
03/03/2005WO2005018655A1 Use of noni in relation to oral pathologies, for example, in order to combat problems associated with asialia and hyposialia
03/03/2005WO2005018650A2 Anti-bacterial composition, especially for controlling gram-negative bacteria, comprising a peptide and an advantageously hydrophobic anti-bacterial agent
03/03/2005WO2005018649A1 Agent for inhibiting the formation of final saccharification product
03/03/2005WO2005018648A1 (20S)-1α-HYDROXY-2-METHYLENE-19-NOR-VITAMIN D3 AND ITS USES
03/03/2005WO2005018647A1 Preventing the crystallization of cholesterol using oxysterols
03/03/2005WO2005018646A1 Ophthalmic composition
03/03/2005WO2005018645A1 A pharmaceutical composition for the prevention and treatment of addiction in a mammal
03/03/2005WO2005018644A1 Capped pyrazinoylguanidine sodium channel blockers
03/03/2005WO2005018642A1 Chemokine inhibiting piperazine derivatives and their use to treat myocarditis
03/03/2005WO2005018641A2 Novel use of quinolone antibiotics
03/03/2005WO2005018640A1 Kit for treatment of upper gastrointestinal tract conditions
03/03/2005WO2005018639A1 Pharmaceutical product for injection
03/03/2005WO2005018635A2 Ion channel modulating activity i
03/03/2005WO2005018634A1 The use of the hernatoporphyrin monomethyl ether for the treatment of the eye disorders
03/03/2005WO2005018633A1 Methods for the amelioration of environmental oxidant stress and the regulation of beneficial genes
03/03/2005WO2005018632A1 Treatment of neurodegenerative conditions
03/03/2005WO2005018631A1 Use of choline derivatives for memory, learning and cognition
03/03/2005WO2005018630A1 Omega-3 fatty acids for the treatment of canine ostheoarthritis
03/03/2005WO2005018629A1 Treatment for acne vulgaris and method of use
03/03/2005WO2005018627A1 Alpha-aminoamide derivatives useful as anti-inflammatory agents
03/03/2005WO2005018626A1 Pharmaceutical composition comprising a combination of metformin and a statin
03/03/2005WO2005018625A1 Use of colipase-lipase inhibitors in the preparation of a pharmaceutical composition in order to prevent obesity
03/03/2005WO2005018624A2 Methods of treating copd and pulmonary hypertension
03/03/2005WO2005018623A2 Parenteral and oral formulations of benzimidazoles
03/03/2005WO2005018622A1 A pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
03/03/2005WO2005018621A1 A pharmaceutical composition for the prevention and treatment of addiction in a mammal
03/03/2005WO2005018620A2 Use of nitric oxide synthase (nos) cofactor for the treatment of sexual dysfunction
03/03/2005WO2005018619A1 Medicament preparations for transdermal application containing active ingredient combinations for treating parkinson's disease
03/03/2005WO2005018616A1 Method for deterring abuse of opioids by combination with non-release formulation of emetic
03/03/2005WO2005018615A1 Tablet containing 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]- methyl}-1-methyl-1h-benzimidazolo-5-carbonyl)-pyridino-2-yl- amino]-ethyl propionate or the salts thereof
03/03/2005WO2005018614A1 Powder formulation comprising the cgrp antagonist 1- (n2-(3,5-dibromo-n-(4-(3,4-dihydro-2(1h)-oxoquinazolin-3-yl)- 1-piperidinyl)carbonyl)-d-tyrosyl)-l-lysyl)-4-(4-pyridinyl)-piperazine
03/03/2005WO2005018610A1 In vivo targeting of dendritic cells
03/03/2005WO2005018608A1 Drug delivery system for sub-tenon’s capsule administration of fine grains
03/03/2005WO2005018605A2 Novel formulation of ropinirole
03/03/2005WO2005018604A2 Novel inhalation powder comprising the cgrp antagonist 1-[n2-[3,5-dibromo-n-[[4-(3,4-dihydro-2(1h)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-d-tyrosyl]-l-lysyl]-4-(4-pyridinyl)-piperazine
03/03/2005WO2005018603A2 Spray-dried amorphous bibn 4096 method for production and use thereof as inhalant
03/03/2005WO2005018601A1 Aqueous pharmaceutical solution containing oxymetazoline and/or xylometazoline
03/03/2005WO2005018583A1 Composition for treatment of tinea pedis and method of use
03/03/2005WO2005018582A2 Compositions containing topical active agents and pentylene glycol
03/03/2005WO2005018578A2 Method of treating cancer with hdac inhibitors
03/03/2005WO2005018577A2 11-deoxy-6,9-ether erythromycin compounds
03/03/2005WO2005018576A2 N-desmethyl-n-substituted-11-deoxyerythromycin compounds
03/03/2005WO2005018574A2 Immunostimulatory combinations and treatments
03/03/2005WO2005018573A2 6-cycloamino-2-quinolinone derivatives as androgen receptor modulator compounds
03/03/2005WO2005018569A2 Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin modulating agent for the treatment of neoplasia
03/03/2005WO2005018568A2 Inhibitors of cathepsin s
03/03/2005WO2005018567A2 Compounds and compositions for the treatment of diabetes and diabetes-related disorders
03/03/2005WO2005018565A2 Compositions for delivering 5-ht agonists across the oral mucosa and methods of use thereof
03/03/2005WO2005018564A2 Compositions of a cyclooxygenase-2 selective inhibitor and a low-molecular-weight heparin for the treatment of central nervous system damage
03/03/2005WO2005018563A2 Compositions of a cyclooxygenase-2 selective inhibitor and a phosphodiesterase inhibitor for the treatment of ischemic mediated central nervous system disorders or injury
03/03/2005WO2005018562A2 Blockade of mtor to prevent a hormonal adaptive response
03/03/2005WO2005018561A2 Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use
03/03/2005WO2005018560A2 Methods of reducing risk of infection from pathogens
03/03/2005WO2005018557A2 Substituted pyridinones
03/03/2005WO2005018556A2 Hydroxylamine substituted imidazo-containing compounds
03/03/2005WO2005018555A2 Lipid-modified immune response modifiers
03/03/2005WO2005018551A2 Oxime substituted imidazo-containing compounds
03/03/2005WO2005018550A2 Enhancement of magnesium uptake in mammals
03/03/2005WO2005018547A2 Mitotic kinesin inhibitors
03/03/2005WO2005018546A2 Compositions for diabetes treatment and prophylaxis
03/03/2005WO2005018545A2 Macrocyclic beta-secretase inhibitors for the treatment of alzheimer's disease
03/03/2005WO2005018544A2 Therapy-enhancing glucan
03/03/2005WO2005018542A2 Use of lactoferrin in prophylaxis against infection and/or inflammation in immunosuppressed subjects
03/03/2005WO2005018541A2 Cox-2 inhibitor and serotonin modulator for treating cns damage
03/03/2005WO2005018532A2 Purine receptor binding compounds
03/03/2005WO2005018531A2 Pharmaceutical compositions, azo-heterocyclic compounds and method for the production and use thereof
03/03/2005WO2005018530A2 Penetrating pharmaceutical foam
03/03/2005WO2005018528A2 Method for the treatment prophylaxis and differential diagnosis of prostatitis
1 ... 4765 4766 4767 4768 4769 4770 4771 4772 4773 4774 4775 4776 4777 4778 4779 4780 4781 4782 4783 4784 4785 ... 7860